Brett Delahunt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4980107/publications.pdf

Version: 2024-02-01

282	16,713	25423	25983
papers	citations	59 h-index	112 g-index

287	287	287	14170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163.	15.2	143
2	Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate, 2022, 82, 576-583.	1.2	3
3	The journal marches on. Pathology, 2022, 54, 1-3.	0.3	2
4	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	3.3	18
5	Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019. European Urology, 2022, , .	0.9	0
6	Detection of perineural invasion in prostate needle biopsies with deep neural networks. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 73-82.	1.4	7
7	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3
8	Histological comparison between predictive value of preoperative 3â€T multiparametric MRI and ⁶⁸Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 71-79.	1.3	45
9	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	1.3	1
10	Tumour-like lesions of the urinary bladder. Pathology, 2021, 53, 44-55.	0.3	11
11	Benign mimics of prostate cancer. Pathology, 2021, 53, 26-35.	0.3	7
12	Gene of the month: DICER1: ruler and controller. Journal of Clinical Pathology, 2021, 74, 69-72.	1.0	26
13	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	1.3	4
14	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24, 398-405.	2.0	2
15	Staging of renal cell carcinoma: current progress and potential advances. Pathology, 2021, 53, 120-128.	0.3	18
16	Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology, 2021, 78, 342-344.	1.6	6
17	Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. Pathology, 2021, 53, 199-204.	0.3	3
18	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1109-1116.	1.4	7

#	Article	IF	Citations
19	Publication metrics: it really is all about the numbers. Pathology, 2021, 53, 561-563.	0.3	2
20	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225â€“31. European Urology, 2021, 79, e141-e142.	0.9	2
21	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. American Journal of Surgical Pathology, 2021, 45, 1118-1126.	2.1	36
22	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	0.6	9
23	Communicating prostate biopsy results. Diagnostic Histopathology, 2021, 27, 283-289.	0.2	3
24	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1527-1533.	2.1	6
25	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsiesâ€"Current Status and Next Steps. European Urology Focus, 2021, 7, 687-691.	1.6	18
26	The emerging role of artificial intelligence in the reporting of prostate pathology. Pathology, 2021, 53, 565-567.	0.3	0
27	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. Journal of Clinical Pathology, 2021, 74, 291-299.	1.0	14
28	The epigenome: key to understanding and predicting gout flares. Pathology, 2021, 53, 824-829.	0.3	1
29	Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. Frontiers in Immunology, 2021, 12, 748741.	2.2	7
30	Reply to Eva CompÃ©rat, Mahul Amin, Victor Reuterâ€™s Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol 2019;76:413â€“5. European Urology, 2020, 77, e28-e29.	0.9	0
31	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	5.1	364
32	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.3	29
33	Borderline Gleason scores: communication is the key. Journal of Clinical Pathology, 2020, 73, 616-617.	1.0	1
34	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. Journal of Clinical Pathology, 2020, 73, 630-635.	1.0	9
35	Gene of the month: TMPRSS2 (transmembrane serine protease 2). Journal of Clinical Pathology, 2020, 73, 773-776.	1.0	71
36	Publication metrics: what do they mean?. Pathology, 2020, 52, 619-620.	0.3	5

#	Article	IF	Citations
37	The utility of artificial intelligence in the assessment of prostate pathology. Histopathology, 2020, 76, 790-792.	1.6	9
38	Personalized histopathology reporting for personalized medicine: a plea for improved communication. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 323-325.	1.4	1
39	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	1.4	20
40	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
41	Macroscopy under the microscope: a critical reappraisal of grossing techniques. Histopathology, 2020, 76, 930-933.	1.6	6
42	Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 693-702.	0.4	48
43	Re-evaluation of Pt staging categories for renal cell carcinoma. Pathology, 2020, 52, S7-S8.	0.3	0
44	Multifocal anastomosing haemangioma of the kidney with intravascular growth and sinus fat invasion: a rare benign mimic of angiosarcoma. Pathology, 2020, 52, 394-396.	0.3	7
45	Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 2020, 77, 284-292.	1.6	19
46	Assessment of tumourâ€associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology, 2019, 74, 284-290.	1.6	24
47	PD â€L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. Apmis, 2019, 127, 554-560.	0.9	11
48	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.3	47
49	Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. European Urology, 2019, 76, 413-415.	0.9	16
50	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	1.4	19
51	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 75, 453-467.	1.6	3
52	Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology, 2019, 51, 349-352.	0.3	3
53	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	1.4	40
54	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928.	1.2	9

#	Article	IF	Citations
55	The International Society of Urological Pathology Education webâ€"a web-based system for training and testing of pathologists. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 577-584.	1.4	11
56	Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 55-66.	0.6	6
57	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). Journal of Clinical Pathology, 2019, 72, 573-578.	1.0	4
58	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureterâ€"Nephroureterectomy and Ureterectomy Specimens. American Journal of Surgical Pathology, 2019, 43, e1-e12.	2.1	5
59	Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?. American Journal of Surgical Pathology, 2019, 43, 1249-1252.	2.1	8
60	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncology, The, 2019, 20, 267-281.	5.1	84
61	Grading of renal cell carcinoma. Histopathology, 2019, 74, 4-17.	1.6	188
62	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.3	19
63	TNM clinical staging of prostate cancer: issues and solutions. BJU International, 2019, 123, 382-384.	1.3	10
64	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). Histopathology, 2019, 74, 377-390.	1.6	14
65	Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with ⁶⁸ Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Journal of Urology, 2019, 201, 815-820.	0.2	64
66	Acute pancreatitis conditioned mesenteric lymph causes cardiac dysfunction in rats independent of hypotension. Surgery, 2018, 163, 1097-1105.	1.0	15
67	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	1.6	36
68	Pathology 50 years on. Pathology, 2018, 50, 3-4.	0.3	1
69	Fuhrman grading is inappropriate for papillary renal cell carcinoma. World Journal of Urology, 2018, 36, 1335-1336.	1.2	3
70	Macroscopic features of prostate cancer. Pathology, 2018, 50, 382-388.	0.3	4
71	A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology, 2018, 72, 481-489.	1.6	2
72	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.3	29

#	Article	IF	Citations
73	Emerging entities in renal cell neoplasia: thyroid-like follicular renal cell carcinoma and multifocal oncocytoma-like tumours associated with oncocytosis. Pathology, 2018, 50, 24-36.	0.3	32
74	Re: Comment on Egevad et al., â€˜Utility of Pathology Imagebase for standardisation of prostate cancer gradingâ€™. Histopathology, 2018, 73, 361-362.	1.6	0
75	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	2.1	22
76	The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1057-1062.	0.7	1
77	Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000â€“2012. BJU International, 2017, 119, 50-56.	1.3	32
78	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	1.2	4
79	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	1.6	37
80	Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 2017, 24, 286-287.	0.5	0
81	Genetic profile of ductal adenocarcinoma of the prostate. Human Pathology, 2017, 69, 1-7.	1.1	20
82	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 2017, 71, 641-647.	1.6	19
83	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Human Pathology, 2017, 63, 149-156.	1.1	89
84	Reply: â€˜A plea for greater standardization in intraductal carcinoma of the prostate â€”greater standardization requires greater evidenceâ€™: let's use the available evidence. Histopathology, 2017, 70, 1013-1014.	1.6	3
85	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. Pathology, 2017, 49, 10-18.	0.3	30
86	The decline of medical publishing: the rise of the pseudo-journal. Pathology, 2017, 49, 673-674.	0.3	0
87	Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology, 2017, 49, 715-720.	0.3	14
88	Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology, 2017, 71, 918-925.	1.6	98
89	Pathology Imagebaseâ€”a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	1.6	19
90	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 335-346.	1.6	165

#	Article	IF	Citations
91	Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e52-e53.	0.9	0
92	Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology, 2017, 70, 504-507.	1.6	22
93	Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure. Anticancer Research, 2017, 37, 6943-6946.	0.5	1
94	One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 2016, 10, 339.	0.3	14
95	Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour deâ€differentiation. Histopathology, 2016, 68, 533-540.	1.6	35
96	International Society of Urological Pathology (<scp>ISUP</scp>) grading of prostate cancer â€“ An <scp>ISUP</scp> consensus on contemporary grading. Apmis, 2016, 124, 433-435.	0.9	152
97	The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2016, 40, 244-252.	2.1	2,256
98	In Regard to Zietman et al. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1126-1127.	0.4	3
99	A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology, 2016, 48, 543-549.	0.3	37
100	New Gleason grading system: Statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 479-480.	0.8	0
101	Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of nonâ€prostatic origin: a comparative study. Apmis, 2016, 124, 263-270.	0.9	28
102	Prostate cancer grading: recent developments and future directions. BJU International, 2016, 117, 7-8.	1.3	19
103	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 68, 475-481.	1.6	48
104	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	1.3	10
105	Reply by the Authors. Urology, 2016, 96, 179-180.	0.5	0
106	Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Journal of Urology, 2016, 196, 1321-1323.	0.2	0
107	From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology, 2016, 50, 325-329.	0.6	31
108	Nodular pulmonary light chain deposition disease. Pathology, 2016, 48, 515-518.	0.3	4

#	Article	IF	Citations
109	Cystic Nephroma in Adults. American Journal of Surgical Pathology, 2016, 40, 1591-1600.	2.1	11
110	Mixed Epithelial and Stromal Tumor of the Kidney. American Journal of Surgical Pathology, 2016, 40, 1538-1549.	2.1	44
111	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
112	Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology, 2016, 48, 398-405.	0.3	42
113	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology, 2016, 40, 858-861.	2.1	37
114	Reply: Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 341-342.	1.6	0
115	Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology, 2016, 69, 599-600.	0.9	14
116	De Novo Renal Neoplasia After Kidney Transplantation According to New 2016 WHO Classification of Renal Tumors. Annals of Transplantation, 2016, 21, 745-754.	0.5	6
117	Steatotic livers are susceptible to normothermic ischemia-reperfusion injury from mitochondrial Complex-Iâ€…dysfunction. World Journal of Gastroenterology, 2016, 22, 4673.	1.4	17
118	The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology, 2015, 47, 515-519.	0.3	48
119	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	1.6	41
120	Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2015, 115, 301-307.	0.3	52
121	ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms. Nature Communications, 2015, 6, 6970.	5.8	135
122	Mesenchymal tumors of adult kidney. Seminars in Diagnostic Pathology, 2015, 32, 160-171.	1.0	14
123	Renal neoplasia: From morphologic to molecular diagnosis. Seminars in Diagnostic Pathology, 2015, 32, 87-89.	1.0	3
124	The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Revista Espanola De Patologia, 2015, 48, 90-96.	0.6	0
125	Issues and challenges associated with classifying neoplasms in percutaneous needle biopsies of incidentally found small renal masses. Seminars in Diagnostic Pathology, 2015, 32, 184-195.	1.0	24
126	The evolving classification of renal cell neoplasia. Seminars in Diagnostic Pathology, 2015, 32, 90-102.	1.0	25

#	Article	IF	Citations
127	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.3	8
128	Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clinical Proteomics, 2015, 12, 24.	1.1	13
129	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	2.9	106
130	The ISUP system of staging, grading and classification of renal cell neoplasia. Journal of Kidney Cancer and VHL, 2014, 1, 26-39.	0.2	41
131	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	1.4	41
132	Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. Modern Pathology, 2014, 27, 765-774.	2.9	32
133	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
134	Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. Histopathology, 2014, 64, 399-404.	1.6	31
135	Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Transâ€Tasman Radiation Oncology Group (<scp>TROG</scp>) 03.04 Randomised Androgen Deprivation and Radiotherapy (<scp>RADAR</scp>) randomized controlled trial for locally advanced prostate cancer. BJU International, 2014, 114, 344-353.	1.3	26
136	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology, 2014, 65, 216-227.	1.6	40
137	Percutaneous renal tumour biopsy. Histopathology, 2014, 65, 295-308.	1.6	19
138	Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors. American Journal of Surgical Pathology, 2014, 38, e35-e49.	2.1	110
139	Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology, 2014, 46, 11-14.	0.3	8
140	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	2.1	155
141	Collecting Duct Carcinoma Versus Renal Medullary Carcinoma. American Journal of Surgical Pathology, 2014, 38, 871-874.	2.1	90
142	Effective maybe, but is it costâ€effective? A reply. Histopathology, 2014, 65, 729-730.	1.6	2
143	Biomarkers in renal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 359-365.	1.4	27
144	Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 559-565.	1.4	26

#	Article	IF	Citations
145	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncology, The, 2014, 15, 1076-1089.	5.1	121
146	Advances in Renal Neoplasia. Urology, 2014, 83, 969-974.	0.5	67
147	Patterns of failure after iodine-125 seed implantation for prostate cancer. Radiotherapy and Oncology, 2014, 112, 68-71.	0.3	4
148	MicroRNAs in Mesenteric Lymph and Plasma During Acute Pancreatitis. Annals of Surgery, 2014, 260, 341-347.	2.1	49
149	Donor kidneys with miliary papillary renal cell neoplasia: The role of the pathologist in determining suitability for transplantation. Annals of Transplantation, 2014, 19, 362-366.	0.5	6
150	Main oncologic endpoints of the TROG 03.04 (RADAR) Trial for men with locally advanced prostate cancer. Journal of Clinical Oncology, 2014, 32, 5004-5004.	0.8	1
151	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research, 2014, 4, 907-15.	1.4	4
152	Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. Anticancer Research, 2014, 34, 6779-84.	0.5	6
153	Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2013, 62, 203-218.	1.6	32
154	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. American Journal of Surgical Pathology, 2013, 37, 1490-1504.	2.1	639
155	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	2.1	922
156	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	2.1	154
157	International Society of Urological Pathology (ISUP) Consensus Conference on Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1463-1468.	2.1	41
158	Premalignant lesions of the urinary bladder. Pathology, 2013, 45, 243-250.	0.3	18
159	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	2.1	118
160	A Novel Grading System for Clear Cell Renal Cell Carcinoma Incorporating Tumor Necrosis. American Journal of Surgical Pathology, 2013, 37, 311-322.	2.1	102
161	Strongly Magnetic Iron Nanoparticles Improve the Diagnosis of Small Tumours in the Reticuloendothelial System by Magnetic Resonance Imaging. PLoS ONE, 2013, 8, e56572.	1.1	12
162	Allergen-Specific CTL Require Perforin Expression To Suppress Allergic Airway Inflammation. Journal of Immunology, 2012, 188, 1734-1741.	0.4	26

#	Article	IF	Citations
163	Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology, 2012, 44, 407-418.	0.3	43
164	Radical prostatectomy reporting: consensus and controversy. Pathology, 2012, 44, S11.	0.3	0
165	Dissecting memory T cell responses to TB: Concerns using adoptive transfer into immunodeficient mice. Tuberculosis, 2012, 92, 422-433.	0.8	10
166	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. Journal of Clinical Pathology, 2012, 65, 106-113.	1.0	37
167	Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, The, 2012, 13, 1260-1270.	5.1	49
168	Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 2012, 105, 184-192.	0.3	39
169	Gleason grading: past, present and future. Histopathology, 2012, 60, 75-86.	1.6	85
170	Therapyâ€associated effects in the prostate gland. Histopathology, 2012, 60, 153-165.	1.6	44
171	Alpha-fetoprotein-producing carcinoma of the renal pelvis exhibiting hepatoid and urothelial differentiation. Anticancer Research, 2012, 32, 4987-91.	0.5	10
172	Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology, 2011, 43, 693-696.	0.3	5
173	International Society of Urological Pathology Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Advances in Anatomic Pathology, 2011, 18, 301-305.	2.4	14
174	Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence. American Journal of Surgical Pathology, 2011, 35, 1134-1139.	2.1	93
175	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens: rationale and organization. Modern Pathology, 2011, 24, 1-5.	2.9	110
176	Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 2011, 43, 410-419.	0.3	9
177	Early organ-specific mitochondrial dysfunction of jejunum and lung found in rats with experimental acute pancreatitis. Hpb, 2011, 13, 332-341.	0.1	22
178	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	2.9	127
179	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology, 2011, 24, 16-25.	2.9	214
180	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathology, 2011, 24, 26-38.	2.9	190

#	Article	IF	Citations
181	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	2.9	234
182	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology, 2011, 24, 48-57.	2.9	239
183	Warming and humidification have no effect on oxidative stress during pneumoperitoneum in rats. Minimally Invasive Therapy and Allied Technologies, 2011, 20, 329-337.	0.6	12
184	FISH scoring on paraffin sections versus single-cell suspension for chromophobe renal carcinoma and renal oncocytoma. Anticancer Research, 2011, 31, 3137-42.	0.5	3
185	CHANGES IN THE MESENTERIC LYMPH PROTEOME INDUCED BY HEMORRHAGIC SHOCK. Shock, 2010, 34, 140-149.	1.0	28
186	Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology, 2010, 42, 330-333.	0.3	14
187	Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney. American Journal of Surgical Pathology, 2010, 34, 1608-1621.	2.1	185
188	Gleason scoring: a comparison of classical and modified (International Society of Urological) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 T	0.3	42
189	Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy. Pathology, 2010, 42, 1-5.	0.3	6
190	Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles. American Journal of Surgical Pathology, 2010, 34, 620-626.	2.1	58
191	Diagnostic Usefulness of Fluorescent Cytogenetics in Differentiating Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. American Journal of Clinical Pathology, 2010, 133, 116-126.	0.4	41
192	The Lung Is an Important Site for Priming CD4 T-Cell-Mediated Protective Immunity against Gastrointestinal Helminth Parasites. Infection and Immunity, 2010, 78, 3753-3762.	1.0	68
193	Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma. Pathology, 2010, 42, 524-533.	0.3	16
194	THE REDOX STATUS OF EXPERIMENTAL HEMORRHAGIC SHOCK AS MEASURED BY CYCLIC VOLTAMMETRY. Shock, 2010, 33, 460-466.	1.0	17
195	Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of Renal Tubular Origin. Archives of Pathology and Laboratory Medicine, 2010, 134, e25-e30.	1.2	37
196	Type 2 and clear cell papillary renal cell carcinoma, and tubulocystic carcinoma: a unifying concept. Anticancer Research, 2010, 30, 641-4.	0.5	13
197	Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. European Urology, 2009, 56, 636-643.	0.9	114
198	Advances and controversies in grading and staging of renal cell carcinoma. Modern Pathology, 2009, 22, S24-S36.	2.9	134

#	Article	IF	Citations
199	Uncommon and recently described renal carcinomas. Modern Pathology, 2009, 22, S2-S23.	2.9	189
200	A further step on the journey. Pathology, 2009, 41, 103-104.	0.3	3
201	Gleason grading: consensus and controversy. Pathology, 2009, 41, 613-614.	0.3	13
202	Accelerating the secondary immune response by inactivating CD4⁺CD25⁺ T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis. European Journal of Immunology, 2008, 38, 695-705.	1.6	37
203	Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance. Modern Pathology, 2008, 21, 1095-1100.	2.9	49
204	Redox status of acute pancreatitis as measured by cyclic voltammetry: Initial rodent studies to assess disease severity*. Critical Care Medicine, 2008, 36, 866-872.	0.4	46
205	Prostate cancer--are ethnic minorities disadvantaged?. Anticancer Research, 2008, 28, 3891-5.	0.5	5
206	Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology, 2007, 39, 459-465.	0.3	81
207	Prostate cancer: the new evidence base for diagnosis and treatment. Pathology, 2007, 39, 537-544.	0.3	14
208	Fuhrman Grading is not Appropriate for Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2007, 31, 957-960.	2.1	152
209	The evolution of collagen expression in sarcomatoid renal cell carcinoma. Human Pathology, 2007, 38, 1372-1377.	1.1	10
210	Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Modern Pathology, 2007, 20, 303-309.	2.9	76
211	Expanding the Histologic Spectrum of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. American Journal of Surgical Pathology, 2006, 30, 1554-1560.	2.1	125
212	Nucleolar Grade But Not Fuhrman Grade is Applicable to Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2006, 30, 1091-1096.	2.1	109
213	Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Modern Pathology, 2006, 19, 488-493.	2.9	126
214	Inactivation of CD4 + CD25 + regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunology and Cell Biology, 2006, 84, 467-474.	1.0	88
215	Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Modern Pathology, 2005, 18, 161-169.	2.9	186
216	Testicular lipomatosis in Cowden's syndrome. Modern Pathology, 2005, 18, 1151-1156.	2.9	38

#	Article	IF	Citations
217	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. Clinical Cancer Research, 2005, 11, 7226-7233.	3.2	89
218	History of the Development of the Classification of Renal Cell Neoplasia. Clinics in Laboratory Medicine, 2005, 25, 231-246.	0.7	49
219	Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Research, 2004, 24, 2069-72.	0.5	31
220	Thyroid Gland Clonality Revisited: The Embryonal Patch Size of the Normal Human Thyroid Gland Is Very Large, Suggesting X-Chromosome Inactivation Tumor Clonality Studies of Thyroid Tumors Have to Be Interpreted with Caution. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3284-3291.	1.8	42
221	Renal dysplasia produced by obstructive uropathy in the fetal lamb. Pathology, 2003, 35, 518-521.	0.3	11
222	Editorial: Genitourinary pathology 120 years on. Pathology, 2003, 35, 465-466.	0.3	0
223	Prostate Biopsy Interpretation. Pathology, 2003, 35, 273.	0.3	0
224	Assessment of ethnic variation in serum levels of total, complexed and free prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations. Pathology, 2003, 35, 480-483.	0.3	5
225	Optimising restriction enzyme cleavage of DNA derived from archival histopathological samples: an improved HUMARA assay. Pathology, 2003, 35, 70-4.	0.3	7
226	Myxosarcoma of the right ventricle: an immunohistochemical and ultrastructural study. Anticancer Research, 2003, 23, 3549-53.	0.5	9
227	Induction of experimental autoimmune encephalomyelitis in the absence of c-Jun N-terminal kinase 2. International Immunology, 2002, 14, 849-856.	1.8	14
228	High Resolution Loss of Heterozygosity Mapping of 17p13 in Thyroid Cancer: Hurthle Cell Carcinomas Exhibit a Small 411-Kilobase Common Region of Allelic Imbalance, Probably Containing a Novel Tumor Suppressor Gene. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4715-4721.	1.8	25
229	Intragenic PTEN/MMAC1 Loss of Heterozygosity in Conventional (Clear-Cell) Renal Cell Carcinoma is Associated with Poor Patient Prognosis. Modern Pathology, 2002, 15, 479-485.	2.9	79
230	Vasectomy and Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 3110.	3.8	66
231	Renal cell neoplasia. Pathology, 2002, 34, 13-20.	0.3	10
232	Loss of Heterozygosity Studies Revisited. Journal of Molecular Diagnostics, 2002, 4, 150-158.	1.2	35
233	Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma. Cancer, 2002, 94, 658-664.	2.0	93
234	Evolution of the degree Doctor of Medicine at the University of Otago. New Zealand Medical Journal, 2002, 115, 135-6.	0.5	0

#	Article	IF	Citations
235	Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Research, 2002, 62, 4554-7.	0.4	119
236	Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Human Pathology, 2001, 32, 590-595.	1.1	328
237	Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovascular Pathology, 2001, 10, 133-136.	0.7	104
238	Serum Creatine Kinase Levels Parallel the Clinical Course for Rhabdomyomatous Wilms Tumor. American Journal of Clinical Pathology, 2001, 116, 354-359.	0.4	5
239	Evolving classification of renal cell neoplasia. Expert Review of Anticancer Therapy, 2001, 1, 576-584.	1.1	10
240	Role of Eosinophils in the Pathogenesis of Mycobacterium bovis BCG Infection in Gamma Interferon Receptor-Deficient Mice. Infection and Immunity, 2000, 68, 2976-2978.	1.0	34
241	The Histopathology of Endocardial Sclerosis. Cardiovascular Pathology, 2000, 9, 161-173.	0.7	40
242	Paratesticular Adenomatoid Tumor: Assessment of Calretinin Immunoexpression and Cell Proliferation Indices. Journal of Urologic Pathology, 2000, 12, 105-116.	0.3	12
243	Monographs on pathology of laboratory animals: urinary system. Pathology, 1999, 31, 175.	0.3	4
244	Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology, 1999, 31, 185-190.	0.3	127
245	CTLA-4 Blockade Enhances the Immune Response Induced by Mycobacterial Infection but Does Not Lead to Increased Protection. Infection and Immunity, 1999, 67, 3786-3792.	1.0	60
246	Fine-needle aspiration cytology of metastatic clear-cell renal carcinoma presenting as a solitary mass in the head of the pancreas. Diagnostic Cytopathology, 1998, 19, 194-197.	0.5	13
247	Cystic embryonal sarcoma of kidney. , 1998, 82, 2427-2433.		26
248	IL-4, IL-5 and IL-10 are not required for the control ofM. bovis-BCG infection in mice. Immunology and Cell Biology, 1998, 76, 41-46.	1.0	40
249	Broadsheet number 45: Thin core biopsy of prostate. Pathology, 1998, 30, 247-256.	0.3	4
250	Polyclonal Ki-67 expression in transitional cell carcinoma of the bladder. Pathology, 1997, 29, 84-87.	0.3	4
251	AgNORs, and Tumor Stage and Grade as Prognostic Markers for Renal Cell Carcinoma. Journal of Histotechnology, 1997, 20, 81-81.	0.2	0
252	Ultrastructure of streptozotocin ? induced renal tumours in mice. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 173-180.	1.4	7

#	Article	IF	Citations
253	The Heidelberg classification of renal cell tumours. , 1997, 183, 131-133.		1,142
254	Classification of renal cell carcinoma. , 1997, 80, 987-989.		768
255	The Heidelberg classification of renal cell tumours. , 1997, 183, 131.		6
256	The Heidelberg classification of renal cell tumours. , 1997, 183, 131.		61
257	Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology, 1996, 28, 321-327.	0.3	63
258	Cytodiagnosis of Hashimoto's thyroiditis associated with a metastatic adenocarcinoma. Diagnostic Cytopathology, 1996, 14, 90-91.	0.5	1
259	Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma. Pathology, 1995, 27, 1-4.	0.3	17
260	THE EFFECT OF FINASTERIDE ON PROSTATE VOLUME, URINARY FLOW RATE AND SYMPTOM SCORE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. Australian and New Zealand Journal of Surgery, 1995, 65, 35-39.	0.2	9
261	Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer, 1995, 75, 2714-2719.	2.0	77
262	Analysis of the prevalence of voiding symptoms in maori, pacific island, and caucasian new zealand men. Urology, 1995, 46, 506-511.	0.5	29
263	Renal cell carcinoma in New Zealand: A national survival study. Urology, 1994, 43, 300-309.	0.5	32
264	AWARENESS OF TESTICULAR CANCER IN NEW ZEALAND MEN. ANZ Journal of Surgery, 1994, 64, 750-753.	0.3	7
265	Rapid Diagnostic Screening of Prostatic Tissue by Low Power Microscopy. Journal of Histotechnology, 1994, 17, 51-53.	0.2	0
266	Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators. Pathology, 1994, 26, 353-358.	0.3	10
267	Familial cystic nephroma and pleuropulmonary blastoma. Cancer, 1993, 71, 1338-1342.	2.0	79
268	Familial cystic nephroma and pleuropulmonary blastoma. Cancer, 1993, 72, 2792-2793.	2.0	14
269	Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: Comparison with tumour grade, mitotic index, and silver-staining nucleolar organizer region numbers. Journal of Pathology, 1993, 170, 471-477.	2.1	67
270	Giant Cystic Nephroma in An Adult. Scandinavian Journal of Urology and Nephrology, 1992, 26, 421-423.	1.4	1

#	Article	IF	Citations
271	Letters to the editor. Journal of Pathology, 1992, 168, 423-426.	2.1	3
272	Nucleolar organizer regions and prognosis in renal cell carcinoma. Journal of Pathology, 1991, 163, 31-37.	2.1	77
273	Testicular Germ Cell Tumor with Pineal Metastases. Neurosurgery, 1990, 26, 688-691.	0.6	10
274	Colonic varices. Diseases of the Colon and Rectum, 1989, 32, 524-527.	0.7	13
275	Early berry aneurysm formation in marfan's syndrome. World Neurosurgery, 1989, 31, 200-202.	1.3	35
276	Dysplastic and malignant areas in hyperplastic polyps of the large intestine. Pathology, 1989, 21, 138-142.	0.3	58
277	Renal cell carcinoma II. Histological indicators of prognosis. Pathology, 1987, 19, 258-263.	0.3	76
278	The Assessment of Urinary Catheter Toxicity Using Cell Cultures: Validation by Comparison with an Animal Model. Journal of Urology, 1986, 136, 706-709.	0.2	22
279	The Assessment of Catheter-Induced Urethritis Using an Experimental Dog Model. Journal of Urology, 1985, 134, 623-625.	0.2	22
280	Suprasellar germinoma with probable extracranial metastases. Pathology, 1982, 14, 215-218.	0.3	6
281	The ependyma of the saccular pineal gland in the non-eutherian mammal Trichosurus vulpecula. Cell and Tissue Research, 1980, 213, 417-32.	1.5	7
282	Intraductal Carcinoma of the Prostate and Nuclear Size. American Journal of Surgical Pathology, 0, Publish Ahead of Print, .	2.1	0